- Conditions
- Primary Biliary Cholangitis
- Interventions
- Seladelpar, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 402 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Lancaster, California + 40 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 337–360
of 2,080
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypereosinophilic Syndrome
- Interventions
- Benralizumab, Placebo
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 130 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 8
- States / cities
- La Jolla, California • Atlanta, Georgia • Bethesda, Maryland + 5 more
- Conditions
- Hypertrophic Cardiomyopathy
- Interventions
- mavacamten
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • New Haven, Connecticut • Durham, North Carolina + 1 more
- Conditions
- Achondroplasia
- Interventions
- Infigratinib
- Drug
- Lead sponsor
- QED Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2032
- U.S. locations
- 8
- States / cities
- Oakland, California • Aurora, Colorado • Wilmington, Delaware + 5 more
- Conditions
- Bioavailability Heathy Volunteers
- Interventions
- FDC (24 mg ER torsemide and 30 mg Spironolactone) without food, FDC (24 mg ER torsemide and 30 mg Spironolactone) with food
- Combination Product
- Lead sponsor
- Sarfez Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Vienna, Virginia
- Conditions
- Exocrine Pancreatic Insufficiency, Cystic Fibrosis
- Interventions
- Liprotamase
- Drug
- Lead sponsor
- Anthera Pharmaceuticals
- Industry
- Eligibility
- 7 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Jackson, Mississippi • Burlington, Vermont
- Conditions
- Major Depressive Disorder
- Interventions
- DVS SR
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 7 Years to 17 Years
- Enrollment
- 269 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 33
- States / cities
- Dothan, Alabama • Goodyear, Arizona • Tucson, Arizona + 26 more
- Conditions
- Healthy
- Interventions
- Clarithromycin ER 500 mg tablets, BIAXIN® XL 500 mg tablets
- Drug
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002
- U.S. locations
- 1
- States / cities
- Saint Charles, Missouri
- Conditions
- Advanced Solid Tumor
- Interventions
- STX-001, Keytruda®
- Biological
- Lead sponsor
- Strand Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Beverly Hills, California • Cleveland, Ohio + 3 more
- Conditions
- PNH
- Interventions
- Pegcetacoplan
- Drug
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Denver, Colorado • Jacksonville, Florida + 6 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Bosentan
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 3 Months to 12 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • New York, New York
- Conditions
- Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease
- Interventions
- macitentan 10 mg
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 11
- States / cities
- Littleton, Colorado • Chicago, Illinois • Iowa City, Iowa + 8 more
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Quadrivalent influenza vaccine, Ofatumumab, iDMT
- Biological · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Hollywood, Florida • St Louis, Missouri
- Conditions
- Migraine, Major Depressive Disorder
- Interventions
- Fremanezumab, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 353 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 17
- States / cities
- Little Rock, Arkansas • San Diego, California • Denver, Colorado + 14 more
- Conditions
- Relapsed or Refractory Follicular Lymphoma
- Interventions
- Mosunetuzumab, Lenalidomide, Rituximab, Tociluzumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 478 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 17
- States / cities
- Duarte, California • Atlanta, Georgia • Fort Wayne, Indiana + 13 more
- Conditions
- Prostate Cancer
- Interventions
- pomegranate liquid extract
- Dietary Supplement
- Lead sponsor
- Roll International Corporation
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Multiple Myeloma
- Interventions
- Cilta-cel, Talquetamab, Daratumumab, Teclistamab, Bortezomib, Lenalidomide, Dexamethasone, Cyclophosphamide, Fludarabine
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 5
- States / cities
- Duarte, California • San Francisco, California • Iowa City, Iowa + 2 more
- Conditions
- Thrombocytopenia
- Interventions
- Avatrombopag, Placebo, Pegylated interferon (PEG-IFN), Telaprevir, Ribavirin
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Fairfax, Virginia
- Conditions
- Rhinoplasty
- Interventions
- Polydioxanone (PDS) plates, Caudal septal extension graft performed through endonasal rhinoplasty
- Device · Procedure
- Lead sponsor
- DeNova Research
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic
- Interventions
- AR882 Dose 1, AR882 Dose 2, Allopurinol Tablet
- Drug
- Lead sponsor
- Arthrosi Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 7 more
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- [Lu-177]-PNT2002, Abiraterone, Enzalutamide
- Drug
- Lead sponsor
- POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 455 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 33
- States / cities
- Tucson, Arizona • Los Angeles, California • Newport Beach, California + 24 more
- Conditions
- Epilepsy, Seizures, Epileptic
- Interventions
- SPN-817
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Miami, Florida
- Conditions
- Fibrodysplasia Ossificans Progressiva
- Interventions
- Andecaliximab, Placebo
- Drug
- Lead sponsor
- Ashibio Inc
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 3
- States / cities
- San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania
- Conditions
- Hepatic Impairment
- Interventions
- Nalbuphine ER
- Drug
- Lead sponsor
- Trevi Therapeutics
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 3
- States / cities
- Miami, Florida • Orlando, Florida